Amgen Inc. $AMGN Stock Holdings Raised by Robeco Institutional Asset Management B.V.

Key Points

• Robeco Institutional Asset Management increased its Amgen stake by 16.5% in the third quarter, adding 95,436 shares to own 675,485 shares valued at approximately $284.7 million. Institutional investors and hedge funds collectively own 76.5% of AMGN.
• Amgen reported quarterly EPS of $6.29 and revenue of $10.05 billion, surpassing analyst expectations, while revenue rose 9.5% year over year. The company also pays a quarterly dividend of $2.52 per share, representing a 2.3% yield.
• AMGN recently traded at $438.94, near its 52-week high, but analysts maintain a consensus “Hold” rating with an average price target of $387.93. Insiders sold 6,222 shares worth about $2.54 million over the past three months.

Robeco Institutional Asset Management B.V. raised its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 16.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 675,485 shares of the medical research company's stock after acquiring an additional 95,436 shares during the period. Robeco Institutional Asset Management B.V. owned approximately 0.12% of Amgen worth $284,724,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. State Street Corp lifted its position in shares of Amgen by 38.2% during the 2nd quarter. State Street Corp now owns 42,205,243 shares of the medical research company's stock worth $15,283,363,000 after purchasing an additional 11,656,755 shares during the last quarter. Bank of America Corp DE bought a new stake in Amgen during the 2nd quarter valued at approximately $1,831,903,000. Wellington Management Group LLP boosted its stake in Amgen by 1,102.7% during the 2nd quarter. Wellington Management Group LLP now owns 2,742,271 shares of the medical research company's stock valued at $993,031,000 after purchasing an additional 2,514,254 shares during the period. BlackRock Inc. grew its holdings in Amgen by 4.8% in the 2nd quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company's stock valued at $17,874,974,000 after buying an additional 2,261,544 shares during the last quarter. Finally, Assenagon Asset Management S.A. grew its holdings in Amgen by 702.8% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,535,257 shares of the medical research company's stock valued at $647,126,000 after buying an additional 1,344,010 shares during the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Amgen

In related news, SVP Nancy A. Grygiel sold 2,970 shares of the company's stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the transaction, the senior vice president directly owned 7,340 shares in the company, valued at approximately $2,951,854.40. This represents a 28.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Rachna Khosla sold 1,252 shares of the company's stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total value of $521,370.36. Following the completion of the transaction, the senior vice president owned 6,404 shares of the company's stock, valued at $2,666,817.72. The trade was a 16.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 6,222 shares of company stock worth $2,540,926 in the last three months. 0.85% of the stock is owned by insiders.

Amgen Stock Up 3.3%

NASDAQ AMGN opened at $438.94 on Wednesday. Amgen Inc. has a twelve month low of $288.00 and a twelve month high of $447.03. The stock has a market cap of $237.30 billion, a PE ratio of 27.28, a PEG ratio of 3.11 and a beta of 0.41. The firm has a 50-day simple moving average of $416.19 and a 200 day simple moving average of $376.06. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%. The firm had revenue of $10.05 billion for the quarter, compared to analyst estimates of $9.43 billion. During the same period in the previous year, the company posted $6.02 earnings per share. The company's quarterly revenue was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, research analysts forecast that Amgen Inc. will post 22.94 EPS for the current year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 11th. Stockholders of record on Friday, August 21st were issued a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a dividend yield of 2.3%. The ex-dividend date of this dividend was Friday, August 21st. Amgen's dividend payout ratio (DPR) is presently 62.65%.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Positive Tezspire Phase 3 results: Amgen and AstraZeneca reported that Tezspire produced statistically significant and clinically meaningful improvements in eosinophilic esophagitis, including sustained symptom improvement and histologic remission through 52 weeks. The data could expand Tezspire’s commercial opportunity beyond severe asthma. Tezspire Phase 3 results
• Positive Sentiment: Upcoming oncology presentation: Amgen will host an investor webcast during the European Society for Medical Oncology Congress on October 24. New cancer-drug data could provide additional visibility into the company’s pipeline and growth prospects. Amgen ESMO 2026 presentation
• Positive Sentiment: Higher analyst valuation: Goldman Sachs raised its price target for AMGN to $481, signaling potential upside from recent trading levels and reinforcing improving sentiment toward the company. Goldman Sachs raises Amgen price target
• Positive Sentiment: Strong financial performance: Amgen recently exceeded consensus estimates for quarterly revenue and earnings per share, with revenue up 9.5% year over year. Investors are increasingly viewing the company’s diversified portfolio as capable of delivering renewed growth.
• Neutral Sentiment: Compared with Bristol Myers Squibb, Amgen offers stronger recent top-line growth, while Bristol Myers has a lower valuation and substantial free cash flow. The comparison highlights AMGN’s growth appeal but also its relatively fuller valuation. Amgen versus Bristol Myers Squibb
• Negative Sentiment: At roughly 27 times earnings, AMGN is not a deep-value healthcare stock, and its high debt-to-equity ratio increases sensitivity to execution and pipeline setbacks. Investors still need evidence that newer products can sustain growth as mature medicines face competition.

Analysts Set New Price Targets

Several research analysts have commented on AMGN shares. Wall Street Zen raised Amgen from a "hold" rating to a "buy" rating in a research report on Sunday. Cantor Fitzgerald increased their price objective on Amgen from $400.00 to $440.00 and gave the company a "neutral" rating in a research report on Monday, October 5th. Robert W. Baird raised their price objective on shares of Amgen from $215.00 to $230.00 and gave the stock an "underperform" rating in a research note on Wednesday, August 5th. TD Cowen raised their price objective on shares of Amgen from $420.00 to $452.00 and gave the stock a "buy" rating in a research note on Wednesday, August 5th. Finally, BMO Capital Markets dropped their target price on shares of Amgen from $450.00 to $415.00 and set a "market perform" rating on the stock in a research report on Monday, October 12th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, sixteen have assigned a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $387.93.

Amgen Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company's products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.